In the last trading session, 1.37 million shares of the Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) were traded, and its beta was 0.66. Most recently the company’s share price was $0.29, and it changed around $0.01 or 7.27% from the last close, which brings the market valuation of the company to $15.56M. SONN currently trades at a discount to its 52-week high of $2.07, offering almost -613.79% off that amount. The share price’s 52-week low was $0.23, which indicates that the current value has risen by an impressive 20.69% since then. We note from Sonnet BioTherapeutics Holdings Inc.’s average daily trading volume that its 3-month average coming to 2.62 million.
Sonnet BioTherapeutics Holdings Inc. stock received a consensus recommendation rating of a Buy, based on a mean score of 1.50. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended SONN as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Sonnet BioTherapeutics Holdings Inc. is expected to report earnings per share of -$0.14 for the current quarter.
Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) trade information
Instantly SONN has showed a green trend with a performance of 7.27% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.2950 on Tuesday, 06/21/22 increased the stock’s daily price by 1.69%. The company’s shares are currently down -28.59% year-to-date, but still up 25.00% over the last five days. On the other hand, Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) is 13.46% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $2.25, which translates to bulls needing to increase their stock price by 87.11% from its current value. Analyst projections state that SONN is forecast to be at a low of $2.00 and a high of $2.50. In order for the stock price to hit the forecast high, the stock would need to plunge -762.07% from its current level, while the stock would need to crash -589.66% from its current level to reach the projected low.
Sonnet BioTherapeutics Holdings Inc. (SONN) estimates and forecasts
The year-over-year growth rate is expected to be -73.10%, down from the previous year.
Consensus estimates provided by 2 financial analysts predict the company will bring in an average of $50k in revenue for the current quarter. 2 analysts expect Sonnet BioTherapeutics Holdings Inc. to make $50k in revenue for the quarter ending Sep 2022.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 54.30%.
Sonnet BioTherapeutics Holdings Inc.’s next quarterly earnings report is expected to be released around February 14 and February 18.
Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 3.17% of Sonnet BioTherapeutics Holdings Inc. shares, and 8.29% of them are in the hands of institutional investors. The stock currently has a share float of 8.56%. Sonnet BioTherapeutics Holdings Inc. stock is held by 23 institutions, with Vanguard Group, Inc. (The) being the largest institutional investor. By Dec 30, 2021, it held 2.93% of the shares, which is about 1.78 million shares worth $0.73 million.
Geode Capital Management, LLC, with 1.86% or 1.13 million shares worth $0.47 million as of Dec 30, 2021, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Fidelity NASDAQ Composite Index ETF were the top two Mutual Funds as of Dec 30, 2021. The former held 1.62 million shares worth $0.67 million, making up 2.67% of all outstanding shares. On the other hand, Fidelity NASDAQ Composite Index ETF held roughly 0.47 million shares worth around $0.14 million, which represents about 0.77% of the total shares outstanding.